The Effects of Antidepressants in Parkinson’s Disease: A Meta-Analysis

REFERENCES

• Allain H., Cougnard J., Neukirch H. C. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT). Acta Neurologica Scandinavica 1991; 136: 73–78
   Web of Science ®Google Scholar
• Anderson J., Aabro E., Gulmann N., Hjelmsted A., Pedersen H. E. Anti-depressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurologica Scandinavica 1980; 62: 210–219
   Web of Science ®Google Scholar
• Caley C. F., Friedman J. H. Does fluoxetine exacerbate Parkinson's disease? Journal of Clinical Psychiatry 1992; 53: 278–282
   Google Scholar
• Ceravolo R., Nuti A., Piccinni A., Dell’Agnell G., Bellini G., Gambaccini G., Dell’Osso L., Murri L., Onnuccelli U. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology 2000; 55: 1216–1218
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Erlbaum, Hillsdale, NJ 1988
   Google Scholar
• Cummings J. L. Depression and Parkinson's disease: A review. American Journal of Psychiatry 1992; 149: 443–454
   PubMed Web of Science ®Google Scholar
• Dalrymple-Alford J. C., Jamieson C. F., Donaldson I. M. G. Effects of selegiline on cognition in early Parkinson's disease. Clinical Neuropharmacology 1995; 18: 348–359
   Google Scholar
• Fiske S. T., Schacter D. L., Zahn-Waxler C. Meta-analysis: Recent developments in quantitative methods for literature reviews. Annual Review of Psychology 2001; 52: 59–82
   Google Scholar
• Glass G. V., McGaw B., Smith M. L. Meta-analysis in social research. Sage Publications, Beverly Hills, CA 1981
   Google Scholar
• Golbe L. I., Duvoisin R. C. Double-blind trial of R-(–)-deprenyl for the “on-off” effect complicating Parkinson's disease. Journal of Neural Transmission 1987; 25: 123–129
   Google Scholar
• Hauser R. A., Zesiewicz T. A. Sertraline for the treatment of depression in Parkinson's disease. Movement Disorders 1997; 12: 756–759
   PubMed Web of Science ®Google Scholar
• Hedges L. V., Olkin I. Statistical methods for meta-analysis. Academic Press, Orlando, FL 1985
   Google Scholar
• Hietanen M. H. Selegiline and cognitive function in Parkinson's disease. Acta Neurologica Scandinavica 1991; 84: 407–410
   Google Scholar
• Hornykiewicz O. Imbalance of brain monoamines and clinical disorders. Progress in Brain Research 1982; 55: 419–421
   Google Scholar
• Hubble J. P., Koller W. C., Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clinical Neuropharmacology 1993; 16: 83–87
   PubMed Web of Science ®Google Scholar
• Indaco A., Carrieri P. D. Amitriptyline in the treatment of headache in patients with Parkinson's disease. Neurology 1988; 38: 1720–1722
   Google Scholar
• Ives N. J., Stowe R. L., Marro J., Counsell C., Macleod A., Clarke C. E., Gray R., Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson's disease: Meta-analysis of 17 randomized trials involving 3525 patients. 2004, Retrieved September 10, 2004, from the Pubmed database. URL=www.ncbi.nlm.gov/pubmed
   Google Scholar
• Jimenez-Jimenez F. J., Tejeiro J., Martinez-Junquera G., Cabrera-Valdivia F., Alarcon J., Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44: 240–246
   Web of Science ®Google Scholar
• Johnson B. T. DSTAT: Software for the meta-analytic review of research literatures. Erlbaum, Hillsdale, NJ 1990
   Google Scholar
• Klaassen T., Verhey F. R. J., Sneijders G. H. J., Rozendaal N., de Vet H. C. W., van Praag H. M. Treatment of depression in Parkinson's disease: A meta-analysis. Journal of Neuropsychiatry and Clinical Neurosciences 1995; 7: 281–286
   PubMedGoogle Scholar
• Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurologica Scandinavica 1969; 45: 109–113
   PubMed Web of Science ®Google Scholar
• Larsen J. P., Boas J., Erdal J. E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish study group. European Journal of Neurology 1999; 6: 539–547
   PubMedGoogle Scholar
• Leentjens A. F. G., Verhey F. R. J., Luijckx G. J., Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Movement Disorders 2000; 6: 1221–1224
   Google Scholar
• Leentjens A. F. G., Vreeling F. W., Luijckx G. J., Verhey F. R. J. SSRIs in the treatment of depression in Parkinson's disease. International Journal of Geriatric Psychiatry 2003; 18: 552–554
   PubMed Web of Science ®Google Scholar
• Lees A. J., Kohout L. J., Shaw K. M., Stern G. M., Elsworth J. D., Sandler M., Youdam M. B. H. Deprenyl in Parkinson's disease. The Lancet 1977; 2: 791–795
   PubMed Web of Science ®Google Scholar
• MacGillivray S., Arroll B., Hatcher S., Ogston S., Reid I., Sullivan F., Williams B., Cromble L. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-analysis. British Medical Journal 2003; 326: 1014–1017
   PubMed Web of Science ®Google Scholar
• Mann J., Gershon S. L-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous depression. Life Science 1980; 2: 877–882
   Google Scholar
• Mann J. J., Aarons S. F., Wilner P. J., Keilp J. G., Sweeney J. A., Pearlstein T., Frances A. J., Kocsis J. H., Brown R. P. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Archives of General Psychiatry 1989; 46: 45–50
   PubMed Web of Science ®Google Scholar
• Mendlewicz J., Youdim B. H. L-deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double blind evaluation. British Journal of Psychiatry 1983; 142: 508–511
   PubMed Web of Science ®Google Scholar
• Montastruc J. L., Fabre N., Blin O., Senard J. M., Rascol O., Roscol A. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Movement Disorders 1995; 10: 355–357
   PubMed Web of Science ®Google Scholar
• Morrison C., Borod J., Brin M., Halbig T., Olanow C. W. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MTSPD). Journal of Neural Transmission 2004; 111: 1333–1341
   PubMed Web of Science ®Google Scholar
• Myllyla V. V., Sotaniemi K. A., Vuorinen J. A., Heinonen E. H. Selegiline as a primary treatment of Parkinson's disease. Acta Neurologica Scandinavica 1991; 84: 70–72
   Google Scholar
• Myllyla V. V., Sotaniemi K. A., Vuorinen J. A., Heinonen E. H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339–343
   PubMed Web of Science ®Google Scholar
• Myllyla V. V., Sotaniemi K. A., Vuorinen J. A., Heinonen E. H. Selegiline in de novo parkinsonian patients: The Finnish study. Movement Disorders 1993; 8: S41–S44
   Web of Science ®Google Scholar
• Myllyla V. V., Heinonen E. H., Vuorinen J. A., Kilkku O. I., Sotaniemi K. A. Early selegiline therapy reduces levodopa dose requirment in Parkinson's disease. Acta Neurologica Scandinavica 1995; 91: 177–182
   Google Scholar
• Myllyla V. V., Sotaniemi K. A., Hakulinen P., Maki-Ikola O., Heinonen E. H. Selegiline as the primary treatment of Parkinson's disease—a long-term double-blind study. Acta Neurologica Scandinavica 1997; 95: 211–218
   PubMed Web of Science ®Google Scholar
• Orwin R. G. A fail safe N for effect size in meta-analysis. Journal for Educational Statistics 1983; 8: 157–159
   Google Scholar
• *Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine 1989; 321: 1364–1371
   Google Scholar
• *Parkinson Study Group. Effects of tocopherol and Deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine 1993; 328: 176–183
   Google Scholar
• Poewe W., Seppi K. Treatment options for depression and psychosis in Parkinson's disease. Journal of Neurology 2001; 248: III/12–III/21
   Google Scholar
• Przuntek H., Kuhn W. The effect of r-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. Journal of Neural Transmission 1987; 25: 97–104
   Google Scholar
• Przuntek H., Conrad B., Dichgans J., Kraus P. H., Krauseneck P., Pergande G., Rinne U., Schimrigk K., Schnitker J., Vogel H. P. SELDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. European Journal of Neurology 1999; 6: 141–150
   PubMed Web of Science ®Google Scholar
• Rampello L., Chiechio S., Raffaele R., Vecchio I., Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clinical Neuropharmacology 2002; 25: 21–24
   PubMed Web of Science ®Google Scholar
• Rosenthal R. Meta-analytic procedures for social research. Sage, Beverly Hills, CA 1984
   Google Scholar
• Shoulson I., Oakes D., Fahn S., Lang A., Langston W. J., LeWitt P., Olanow W., Penney J. B., Tanner C., Kieburtz K., Rudolph A., the Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology 2002; 51: 604–612
   PubMed Web of Science ®Google Scholar
• Slaughter J. R., Slaughter K. A., Nichols D., Holmes S. E., Martens M. P. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neuroscience 2001; 13: 187–196
   PubMed Web of Science ®Google Scholar
• Strang R. R. Imipramine in treatment of Parkinsonism: A double-blind placebo study. British Medical Journal 1965; 2: 33–34
   PubMedGoogle Scholar
• Takahashi M., Yuasa R., Imai T., Tachibana H., Yorifuji S., Nakamura Y., Ogawa N. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: A double-blind trial. Internal Medicine 1994; 33: 517–524
   PubMed Web of Science ®Google Scholar
• Tesei S., Antonini A., Canesi M., Zecchinelli A., Mariani C. B., Pezzoli G. Tolerability of paroxetine in Parkinson's disease: A prospective study. Movement Disorders 2000; 15: 986–989
   PubMed Web of Science ®Google Scholar
• Waters C. H., Sethi K. D., Hauser R. A., Molho E., Bertoni J. M., the Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders 2004; 19: 426–432
   PubMed Web of Science ®Google Scholar
• Weintraub D., Morales K. H., Moberg P. J., Bilker W. B., Balderston C., Duda J. E., Katz I. R., Stern M. B. Antidepressant studies in Parkinson's disease: A review and meta-analysis. Movement Disorders 2005; 20: 1161–1169
   PubMed Web of Science ®Google Scholar
• Wermuth L., Sorensen P. S., Timm S., Christensen B., Utzon N. P., Boas J., Dupont E., Hansen E., Magnussen I., Mikkelsen B., Worm-Petersen J., Lauritzen L., Bayer L., Bech P. Depression in idiopathic Parkinson's disease treated with citalopram. Nord Journal of Psychiatry 1998; 52: 163–169
   Web of Science ®Google Scholar
• Wilson K., Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: A meta-analysis. International Journal of Geriatric Psychiatry 2004; 19: 754–762
   PubMed Web of Science ®Google Scholar
• Zgaljardic D., Borod J., Foldi N., Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: Relationship to fronto-striatal circuitry. Cognitive Behavioral Neurology 2003; 16: 193–210
   PubMedGoogle Scholar